| Q39136403 | 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. |
| Q53600744 | 'Genotype/immunotype' correlations in resected NSCLC. |
| Q45718710 | 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization |
| Q54139665 | 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. |
| Q46863819 | 4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells |
| Q58790788 | A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers |
| Q95319497 | A guide to cancer immunotherapy: from T cell basic science to clinical practice |
| Q58696044 | A neoepitope derived from a novel human germline APC gene mutation in familial adenomatous polyposis shows selective immunogenicity |
| Q90648467 | Actively personalized vaccination trial for newly diagnosed glioblastoma |
| Q90677024 | Adaptive Immunity and the Tumor Microenvironment |
| Q90479566 | Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research |
| Q90398709 | Adoptive Cell Therapy-Harnessing Antigen-Specific T Cells to Target Solid Tumours |
| Q89823519 | Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma |
| Q38783946 | Advances in personalized cancer immunotherapy. |
| Q45875006 | An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. |
| Q64070843 | Antigen Targets for the Development of Immunotherapies in Leukemia |
| Q64118726 | Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance |
| Q93052202 | Apparent Lack of BRAF V600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis |
| Q60047537 | CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success |
| Q58606449 | CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors |
| Q37029731 | CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer |
| Q41808474 | CD74 and intratumoral immune response in breast cancer |
| Q36889067 | Cancer immunotherapy targeting neoantigens |
| Q64931054 | Cancer immunotherapy: broadening the scope of targetable tumours. |
| Q60933076 | Cancer research in the era of immunogenomics |
| Q49260236 | Cancer vaccine: learning lessons from immune checkpoint inhibitors |
| Q33806351 | Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators |
| Q90254063 | Challenges towards the realization of individualized cancer vaccines |
| Q38854579 | Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer. |
| Q57180053 | Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant |
| Q39092611 | Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia |
| Q64122192 | Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma |
| Q38698210 | Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity |
| Q91341294 | Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC |
| Q53740080 | Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. |
| Q38885361 | Computational genomics tools for dissecting tumour-immune cell interactions |
| Q55034685 | Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. |
| Q90194707 | Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer |
| Q99237757 | Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer |
| Q38780728 | Current status and future prospects of peptide-based cancer vaccines |
| Q26745516 | Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy |
| Q92284774 | Deciphering CD4+ T cell specificity using novel MHC-TCR chimeric receptors |
| Q90580775 | Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification |
| Q39243064 | Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients. |
| Q91782530 | Determinants for Neoantigen Identification |
| Q90576547 | Developing neoantigen-targeted T cell-based treatments for solid tumors |
| Q40178906 | Development of an epitope panel for consistent identification of antigen-specific T-cells in humans |
| Q47716902 | Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma |
| Q42143897 | Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry |
| Q40062688 | Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial. |
| Q51275962 | Emerging biomarkers for PD-1 pathway cancer therapy. |
| Q36340870 | Emerging role of mutations in epigenetic regulators including MLL2 derived from The Cancer Genome Atlas for cervical cancer |
| Q57029270 | Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy |
| Q92782148 | Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models |
| Q59812766 | Epigenetic Heterogeneity in Human Colorectal Tumors Reveals Preferential Conservation And Evidence of Immune Surveillance |
| Q37147632 | Future perspectives in cancer immunotherapy |
| Q90618258 | Gene editing and CRISPR in the clinic: current and future perspectives |
| Q37430859 | Gene expression and pathway analysis of CTNNB1 in cancer and stem cells |
| Q38774775 | Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease. |
| Q52587406 | Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. |
| Q36730827 | Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma |
| Q92179996 | Genomic correlates of response to immune checkpoint blockade |
| Q91956657 | Genomics-Guided Immunotherapy for Precision Medicine in Cancer |
| Q38806243 | Harnessing the immune system for the treatment of melanoma: current status and future prospects. |
| Q38390185 | Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy. |
| Q47152763 | Hypothesis: Induction of biomarkers for detection of colonic neoplasms |
| Q47133741 | Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients |
| Q36194803 | Identification and isolation of antigen-specific cytotoxic T lymphocytes with an automated microraft sorting system. |
| Q42078847 | Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma |
| Q61445099 | Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas |
| Q47736099 | Identification of essential genes for cancer immunotherapy. |
| Q62050532 | Identifying neoantigens for use in immunotherapy |
| Q90027962 | Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges |
| Q91451443 | Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma |
| Q89655603 | Immune engineering: from systems immunology to engineering immunity |
| Q57118558 | Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer |
| Q39057617 | Immune targets and neoantigens for cancer immunotherapy and precision medicine |
| Q39144327 | Immune-Mediated Therapies for Liver Cancer. |
| Q90215738 | Immunogenic neoantigens derived from gene fusions stimulate T cell responses |
| Q37481401 | Immunogenicity of self tumor associated proteins is enhanced through protein truncation |
| Q49483662 | Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens |
| Q41127026 | Immunoscore in mismatch repair-proficient and -deficient colon cancer. |
| Q41012572 | Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ |
| Q67201060 | Immunotherapy for Glioblastoma: Adoptive T-cell Strategies |
| Q92626003 | Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches |
| Q50034111 | Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma |
| Q47729557 | Immunotherapy of cancer: targeting cancer during active disease or during dormancy? |
| Q94475664 | In Silico analyses of host immunity and stroma provide prognostic factors in early stage pancreatic ductal adenocarcinoma (PDAC) |
| Q92126199 | Induction of neoantigen-reactive T cells from healthy donors |
| Q38864070 | Inflammation as a driver and vulnerability of KRAS mediated oncogenesis |
| Q89965765 | Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment |
| Q37548587 | Ionic immune suppression within the tumour microenvironment limits T cell effector function. |
| Q47279363 | Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens: Nothing New in Spite of the Name |
| Q42348082 | Is Tolerance Broken in Autoimmunity? |
| Q38797183 | Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. |
| Q89730893 | KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures |
| Q40242985 | Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer |
| Q52372679 | Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. |
| Q64279278 | Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides |
| Q36021163 | Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. |
| Q90228169 | Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers |
| Q45459148 | Lung Cancer Subtypes Generate Unique Immune Responses |
| Q91671018 | Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors |
| Q47947510 | Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma |
| Q38740015 | Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes |
| Q52382940 | Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. |
| Q34522172 | Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy |
| Q61124550 | Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients |
| Q47153393 | Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma |
| Q46056233 | Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology |
| Q47292249 | Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. |
| Q38380080 | Monitoring immune responses in the tumor microenvironment |
| Q64079285 | Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma |
| Q37109573 | Mutanome and expression of immune response genes in microsatellite stable colon cancer |
| Q90067743 | Mutated RAS: Targeting the "Untargetable" with T Cells |
| Q42777878 | Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T cell Epitopes & Immune Signatures in a Subset of Prostate Cancer |
| Q92137757 | Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors |
| Q38761397 | Neoantigen landscape dynamics during human melanoma-T cell interactions |
| Q97644519 | Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal |
| Q26738693 | Neoantigen-based cancer immunotherapy |
| Q92332582 | Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4 |
| Q58086853 | Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer |
| Q49711158 | New Chimeric Antigen Receptor Design for Solid Tumors |
| Q89456690 | Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer |
| Q46512368 | Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy |
| Q38812269 | Opportunities and challenges for TCR mimic antibodies in cancer therapy |
| Q26738680 | Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines |
| Q61448030 | Pancreatic cancer microenvironment: a current dilemma |
| Q92504704 | Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches |
| Q48156858 | Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy |
| Q93052152 | Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8+ T cell responses |
| Q37059928 | Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy |
| Q50906889 | Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. |
| Q64988012 | Personalized cancer neoantigen vaccines come of age. |
| Q59136533 | Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment |
| Q99551753 | Point mutation screening of tumor neoantigens and peptide-induced specific cytotoxic T lymphocytes using The Cancer Genome Atlas database |
| Q47701712 | Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer |
| Q92830570 | Precision Medicine-Enabled Cancer Immunotherapy |
| Q38810911 | Precision medicine in pediatric oncology: Lessons learned and next steps |
| Q90704104 | Predicting HLA class II antigen presentation through integrated deep learning |
| Q31148562 | Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing. |
| Q61698755 | Principles of adoptive T cell therapy in cancer |
| Q57191808 | Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences |
| Q94503515 | Prognostic value of CD73 expression in resected colorectal cancer liver metastasis |
| Q98771735 | Progress in Neoantigen Targeted Cancer Immunotherapies |
| Q33913077 | Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment |
| Q34507561 | Prospects for gene-engineered T cell immunotherapy for solid cancers. |
| Q52691915 | Quiescent Tissue Stem Cells Evade Immune Surveillance. |
| Q58698657 | RNA editing derived epitopes function as cancer antigens to elicit immune responses |
| Q40788906 | Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination |
| Q37593573 | Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation |
| Q38819745 | Recent advances in immuno-oncology and its application to urological cancers |
| Q28067217 | Recent advances in understanding antitumor immunity |
| Q90086342 | Recent insights into the biology of pancreatic cancer |
| Q90688967 | Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes |
| Q99237818 | Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models |
| Q26738301 | Regulation of CTNNB1 signaling in gastric cancer and stem cells |
| Q53850924 | Rekindling cancer vaccines. |
| Q90704110 | Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes |
| Q39304787 | Safety of Intra-Arterial Injection With Tumor-Activated T Cells to the Rabbit Brain Evaluated by MRI and SPECT/CT. |
| Q42654278 | Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation |
| Q93104450 | Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy |
| Q41635793 | Socializing Individualized T-Cell Cancer Immunotherapy |
| Q37043492 | Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. |
| Q92242813 | Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy Resistance |
| Q30252919 | Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer |
| Q47335259 | Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy |
| Q52691832 | Strategies for Increasing Pancreatic Tumor Immunogenicity. |
| Q90629190 | Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma |
| Q38992976 | T Cell Genesis: In Vitro Veritas Est? |
| Q92245345 | T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance |
| Q30832820 | T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. |
| Q88938409 | T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers |
| Q55518760 | TCRmodel: high resolution modeling of T cell receptors from sequence. |
| Q50130464 | Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications. |
| Q37223669 | Targeting neoantigens for cancer immunotherapy |
| Q39149196 | Targeting neoantigens to augment antitumour immunity |
| Q34677333 | Targeting of cancer neoantigens with donor-derived T cell receptor repertoires |
| Q97519028 | The Connection Between Minor H Antigens and Neoantigens and the Missing Link in Their Prediction |
| Q64075706 | The Discovery of Biomarkers in Cancer Immunotherapy |
| Q39152114 | The Heterocellular Emergence of Colorectal Cancer |
| Q89080863 | The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity |
| Q90677037 | The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier |
| Q41673084 | The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy |
| Q49307766 | The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy |
| Q38753386 | The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer |
| Q91933780 | The Spatial and Genomic Hierarchy of Tumor Ecosystems Revealed by Single-Cell Technologies |
| Q36129950 | The Value of Online Algorithms to Predict T-Cell Ligands Created by Genetic Variants |
| Q98771269 | The Ways of Isolating Neoantigen-Specific T Cells |
| Q38833922 | The case for immune-based approaches in biliary tract carcinoma |
| Q91520697 | The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy |
| Q54967177 | Towards a better cancer precision medicine: systems biology meets immunotherapy. |
| Q96641056 | Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire |
| Q47789519 | Towards personalized, tumour-specific, therapeutic vaccines for cancer. |
| Q99633734 | Transcriptional and immunohistological assessment of immune infiltration in pancreatic cancer |
| Q39280840 | Treating Hepatobiliary Cancer: The Immunologic Approach |
| Q93157712 | Tumor neoantigens: from basic research to clinical applications |
| Q101166677 | Tumor-infiltrating lymphocytes in the immunotherapy era |
| Q92523541 | Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers |
| Q38787035 | Unmasking targets of antitumor immunity via high-throughput antigen profiling |
| Q40048119 | Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices |
| Q36905613 | Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. |
| Q91517668 | Ushering in Integrated T Cell Repertoire Profiling in Cancer |
| Q93081824 | Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types |
| Q100761752 | Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers |
| Q39013357 | mRNA Cancer Vaccines |
| Q64068516 | α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas |